How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,054 results for

Pruritus in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. In-Use Test With a Cosmetic Product to Treat Pruritus

In-Use Test With a Cosmetic Product to Treat Pruritus In-Use Test With a Cosmetic Product to Treat Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. In-Use Test With a Cosmetic Product to Treat (...) Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03477058 Recruitment Status : Completed First Posted : March 26, 2018 Last Update Posted : August 13, 2018 Sponsor: Dr. August Wolff GmbH & Co. KG Arzneimittel Collaborator: SIT Skin Investigation and Technology Hamburg GmbH Information provided

2018 Clinical Trials

22. Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2018 Clinical Trials

23. Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients

with current treatment Active infection with current treatment Current itching with dermatologic diseases other than uremic pruritus Pregnancy, childbearing potential during the study period, or breastfeeding Allergy or hypersensitivity reaction to PG102P History of participating another clinical trial within 2 months or planning to participate another clinical trial Not eligible to participate this trial as researchers' decision Contacts and Locations Go to Information from the National Library (...) Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety and Efficacy

2018 Clinical Trials

24. Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis

serology for hepatitis B, hepatitis C, HIV indicating acute or chronic infection; Chronic recurring bacterial infections or active TB; Positive pregnancy test at Screening or at the Baseline visit; Female subjects who are pregnant or breast-feeding or considering becoming pregnant during the study; History of clinically significant alcohol or drug abuse in the last 12 months; Known hypersensitivity to the excipients of Otezla® as stated in the label; Subject is considered by the Investigator, for any (...) Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Apremilast

2018 Clinical Trials

25. RDD1609 as a Treatment for Idiopathic Pruritus Ani

RDD1609 as a Treatment for Idiopathic Pruritus Ani RDD1609 as a Treatment for Idiopathic Pruritus Ani - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. RDD1609 as a Treatment for Idiopathic Pruritus Ani (...) by (Responsible Party): RDD Pharma Ltd Study Details Study Description Go to Brief Summary: This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani. Condition or disease Intervention/treatment Phase Idiopathic Pruritus Ani Drug: RDD1609 Drug: Mebendazole 100 MG Phase 2 Detailed Description: This is a phase 2a randomized double-blinded placebo-controlled cross-over design study in patients with idiopathic

2018 Clinical Trials

26. Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus

Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03758079 Recruitment Status : Completed First Posted : November 29, 2018 Last Update Posted : November 29, 2018 Sponsor: University of Balamand Information provided by (Responsible

2018 Clinical Trials

27. Nausea/vomiting in pregnancy

is it? Most women feel nauseated or vomit in early pregnancy [ ]. This is defined as nausea and vomiting in pregnancy when there are no other causes [ ]. These symptoms are commonly referred to as 'morning sickness', but symptoms can occur at any time during the day [ ]. A UK study found that nausea and vomiting occur throughout the day in many pregnant women; of 292 women with symptoms, only 3.8% experienced nausea only in the morning. A similar pattern was observed for women with vomiting (...) and vomiting are a mechanism to prevent the woman eating potentially harmful foods. Gastric dysfunction In pregnant women, oesophageal, gastric, and small-bowel motility are impaired because of smooth-muscle relaxation due to increased levels of progesterone. Delayed gastric emptying in pregnancy may also contribute to nausea and vomiting. Vestibular and olfactory system It is postulated that a pregnancy stimulus may lower the threshold for vestibular-mediated nausea and vomiting in some women. Hyperacuity

2018 NICE Clinical Knowledge Summaries

28. Liver Disease and Pregnancy

Liver Disease and Pregnancy nature publishing group 1 © 2016 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY PRACTICE GUIDELINES To determine the level of evidence, the results from the selected papers with the greatest level of evidence were extrapolated and utilized in the GRADE program ( h t t p://w w w .gradep r o .o r g ). A summary of the recommendations are outlined in Table 1 . EVALUATION OF THE PREGNANT PATIENT WITH ABNORMAL LIVER ENZYMES (...) Recommendations: 1. A pregnant patient presenting with abnormal liver tests should undergo standard workup as with any non-pregnant individual (strong recommendation, very low level of evidence). Th e basis for the workup of abnormal liver tests in a pregnant woman should be predicated on understanding the normal physi- ological changes observed during pregnancy. Th e incidence of abnormal liver tests in pregnant women is ~3–5%, even in this relatively young and healthy population. Some liver test results

2016 American College of Gastroenterology

29. Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes. Full Text available with Trip Pro

into the mild ICP (serum bile acids (SBA) ≤40 μmol/L throughout pregnancy) and severe ICP (SBA >40 μmol/L during pregnancy but fell after ursodeoxycholate therapy) groups. Baseline characteristics, laboratory investigations, and maternal and neonatal outcomes were assessed. Logistic regression was used to identify factors associated with meconium staining of amniotic fluid (MSAF) and APOs.Seventy-three patients were included (mild ICP group, n=47; severe ICP group, n=26). Pruritus was more common (...) Women successfully treated for severe intrahepatic cholestasis of pregnancy do not have increased risks for adverse perinatal outcomes. Intrahepatic cholestasis of pregnancy (ICP) increases adverse perinatal outcome (APO) incidence. Whether successful treatment of severe ICP reduces APO risk is unclear.This retrospective, single-center study in China enrolled consecutive women with ICP who had term delivery (≥37 weeks, singleton) between August 2013 and June 2016. Patients were divided

2019 Medicine

30. Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03322137 Recruitment Status : Completed First Posted : October 26, 2017 Last Update Posted

2017 Clinical Trials

31. Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis

consistent with severe pruritus. WI-NRS scores during the 2 weeks of screening consistent with sever pruritus. All female subjects who are of childbearing potential must be willing to practice highly effective contraception (i.e., pregnancy prevention method with a failure rate of < 1% per year) from the time of the initial Screening visit until 2 weeks after last dose of study drug. Weight ≥ 32 kg at the Screening and Baseline visits. Willing and able to complete daily eDiary entries within a consistent (...) Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2017 Clinical Trials

32. Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

to comply with the study schedules and all study requirements; Males or females 18 years of age or older; Currently on hemodialysis for end-stage renal disease and has been categorized as experiencing moderate to severe uremic pruritus; If female: Is not of childbearing potential (surgically sterile or postmenopausal, as defined in Section 6.5.1.6); or Has a negative serum pregnancy test at screening and agrees to use acceptable contraceptive measures (as defined in Section 6.5.1.6) from the time (...) Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

33. Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients? Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients? - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients? The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03262038 Recruitment Status : Recruiting First Posted : August 25

2017 Clinical Trials

34. Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid

Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid (PRURIPB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03272958 Recruitment Status : Completed First Posted : September 6, 2017 Last

2017 Clinical Trials

35. Risk Factors for Postoperative Nausea, Vomiting and Pruritus

Risk Factors for Postoperative Nausea, Vomiting and Pruritus Risk Factors for Postoperative Nausea, Vomiting and Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Risk Factors for Postoperative (...) Nausea, Vomiting and Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03178058 Recruitment Status : Recruiting First Posted : June 6, 2017 Last Update Posted : June 6, 2017 See Sponsor: Rabin Medical Center

2017 Clinical Trials

36. Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section

Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Serum (...) Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03209427 Recruitment Status : Completed First Posted : July 6, 2017 Last Update Posted : July 6, 2017 Sponsor: Assiut University Information provided by (Responsible Party): Mohamed galal

2017 Clinical Trials

37. A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of SK-1405 (...) in Hemodialysis Patients With Uremic Pruritus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03218501 Recruitment Status : Completed First Posted : July 14, 2017 Last Update Posted : March 8, 2019 Sponsor: Sanwa Kagaku Kenkyusho Co., Ltd. Information provided by (Responsible Party): Sanwa Kagaku Kenkyusho Co

2017 Clinical Trials

38. Dyspepsia - pregnancy-associated

age, with 30–80% of women suffering from dyspepsia at some time during their pregnancy [ ; ; ; ; ]. A prospective longitudinal cohort study of the evolution of GORD symptoms during pregnancy found that [ ]: Of pregnant women, 12.5% had heartburn at least once a week in the first trimester, 21.5% in the second trimester, and 35.3% in the third trimester. Daily heartburn occurred in around 10% of women in the third trimester. In the third trimester, 40.7% of women experienced regurgitation at least (...) once a week (compared with 3.6% of non-pregnant women). Risk factors What are the risk factors? The following risk factors have been associated with gastro-oesophageal reflux symptoms in pregnancy: Symptoms of gastro-oesophageal reflux prior to pregnancy. Increasing gestational age. Parity. The evidence for the following risk factors is less certain: Pre-pregnancy body mass index (BMI). Weight gain during pregnancy. Maternal age. [ ; ; ] Complications What are the complications? Symptoms usually

2017 NICE Clinical Knowledge Summaries

39. Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management. (Abstract)

Intrahepatic Cholestasis of Pregnancy: A Review of Diagnosis and Management. Intrahepatic cholestasis of pregnancy (ICP) complicates approximately 0.2% to 2% of pregnancies and can lead to increased fetal risks in pregnancy.This review aims to increase the knowledge of women's health care providers regarding the diagnosis, management, and fetal risks associated with ICP.The diagnosis of ICP is based on symptoms of pruritus that typically include the palms and soles, as well as elevated bile (...) pruritus symptoms, as well as biochemical tests, but no treatment has been shown to definitively improve fetal outcomes.Providers should be aware of the signs and symptoms of ICP and provide accurate diagnosis and management of affected women. Women with a diagnosis of ICP should be treated with ursodeoxycholic acid to improve maternal symptoms. Given the increased risk of stillbirth in the setting of ICP, delivery may be considered at 37 weeks' gestation.

2018 Obstetrical & Gynecological Survey

40. Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES) Full Text available with Trip Pro

Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES) Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder specific to pregnancy and presents with maternal pruritus, raised concentrations of serum bile acids and abnormal liver function tests. ICP is associated with increased rates of spontaneous and iatrogenic preterm labour, fetal (...) hypoxia, meconium-stained amniotic fluid and intrauterine death. Some clinicians treat ICP with ursodeoxycholic acid (UDCA) to improve maternal pruritus and biochemical abnormalities. However, there are currently no data to support the use of UDCA to improve pregnancy outcome as none of the trials performed to date have been powered to address this question.The PITCHES trial is a triple-masked, placebo-controlled randomised trial, to evaluate UDCA versus placebo in women with ICP between 20 + 0 to 40

2018 Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>